Open Access

Sputum matrix metalloproteinase-9 is associated with the degree of emphysema on computed tomography in COPD

  • Rekha Chaudhuri1,
  • Charles McSharry1,
  • Mark Spears1,
  • Jeffrey Brady2, 3, 4,
  • Christal Grierson2, 3, 4,
  • C Martina Messow5,
  • Gino Miele2, 3, 4,
  • Karl Nocka2, 3, 4,
  • William MacNee6,
  • Martin Connell6,
  • John T Murchison6,
  • Michael Sproule7,
  • Omar Hilmi8,
  • Douglas K Miller2, 3, 4 and
  • Neil C Thomson1Email author
Translational Respiratory Medicine20131:11

DOI: 10.1186/2213-0802-1-11

Received: 16 April 2013

Accepted: 24 May 2013

Published: 6 June 2013



Matrix-metalloproteinase (MMP)-9 has been implicated in the pathogenesis of COPD, although its link to disease severity is unclear. The purpose of the study was to examine the relationship between disease severity assessed by lung function and computed tomography (CT) and sputum MMP-9 expression, concentration and activity in patients with COPD.


In 53 COPD subjects, smokers and ex-smokers; 46 healthy controls, smokers and never smokers, we measured sputum MMP-9 concentrations (ELISA) and enzyme activity (FRET), sputum MMP-9 mRNA expression, spirometry, diffusing capacity for carbon monoxide (DLco) and CT assessment of emphysema (% low attenuation areas below-950 Hounsfield units).

Sputum MMP-9 concentrations and mRNA expression in COPD subjects were significantly greater than in healthy never-smokers (p = 0.007 and p = 0.001 respectively) and similar to those in healthy smokers. Disease severity when assessed by the extent of emphysema measured by CT, but not by spirometry or DLco values, was directly associated with sputum MMP-9 concentrations [r = 0.442 (0.171, 0.634), p = 0.020], and MMP-9 activity [r = 0.447 (0.219, 0.643), p = 0.010]. In moderate to severe COPD, increased MMP-9 mRNA expression levels were associated with reduced post-bronchodilator FEV1 [r = −0.530 (−0.686, -0.327), p < 0.001], FEV1/FVC ratio [r = −0.551 (−0.701, -0.354), p < 0.001] and reduced DLco [r = −0.399 (−539, -0.102), p = 0.048].


Sputum MMP-9 concentrations in COPD are directly associated with the extent of emphysema measured by CT and MMP-9 expression levels are inversely associated with DLco. These findings support a role for MMP-9 in the pathogenesis of COPD.


MMP-9 MMP-9 expression COPD Computed tomography


Inappropriate expression and excessive activity of several matrix metalloproteinases (MMP), including MMP-9 [1, 2] has been implicated in the tissue destructive processes associated with chronic lung diseases including COPD [27]. Increased sputum MMP-9 protein concentrations and/or activity are reported in current smokers with COPD compared to healthy smokers [8, 9]. However, a definitive role of MMP-9 in the development of emphysema is uncertain. For example, mice deficient in MMP-9 develop the same degree of cigarette smoke-induced inflammation and airspace enlargement as control mice and human macrophages MMP-9 mRNA is present in areas of lung irrespective of the presence of emphysema [10]. Nevertheless circulating monocytes from subjects with advanced emphysema on computed tomography (CT) produced more MMP-9 than controls [10]. In previous clinical studies there is a lack of information about concentrations, activities and expression of MMP-9 in well characterized patients with COPD and it is unknown whether MMP-9 activity is linked to disease severity. The aim of the study was to test the hypothesis that MMP-9 concentrations and activity in COPD are associated with disease severity as assessed by lung function and computed tomography.



A cross sectional study was performed in subjects with COPD and healthy controls as part of the Glasgow COPD and Asthma Biomarker study [7]. Clinical, physiological and immunological plus imaging (COPD groups only) measurements were performed at baseline. Participants were recruited with mild, moderate and severe COPD (GOLD stages I (n = 14), II (n = 23) and III (n = 16) [11]; (both current smokers and ex-smokers), and healthy smokers and never smokers, defined as volunteers with no known respiratory disease, no chronic respiratory symptoms and normal spirometry.

The West Glasgow Research Ethics Committee approved the study and all patients gave written informed consent.


Spirometry was performed according to American Thoracic Society guidelines [12]. Lung volumes and diffusing capacity for carbon monoxide (DLco) were performed using the body box technique (Zan500 Body Plethysmography, nSpire Health Limited, Hertford, UK). Sputum induction was performed as previously described [7]. CT scans of the Chest were performed at full inspiration using 16 slice Brightspeed and 64 slice Lightspeed (GE CT scanner, Milwaukee, Wisconsin, USA) with the following parameters: 120 KV, 100 mAs, collimation 1mm, reconstruction slice thickness 0.65mm, reconstruction slice separation 0.5mm, pitch of 1 and the data was reconstructed with a CHST filter. All scans were evaluated centrally at the University of Edinburgh. Emphysema was quantified as the percentage of lung CT voxels below a threshold of −950 Hounsfield Units-% low attenuation areas (LAA)-950, using the software Pulmonary Workstation 2.0 (VIDA Diagnostics, Iowa City, IA, USA) as described previously [1315]. MMP-9 ELISA and MMP-9 activity kits (fluorescence resonance energy transfer (FRET) method) were supplied by R&D Systems Europe Ltd. (Cat. Nos. DMP900 and F9M00 respectively; Abingdon, UK). Assays were performed in accordance with the instructions provided; however the activity assay was read kinetically over 4 hours as this showed better reproducibility than an end-point read-out. Samples were not chemically activated with amino-phenyl mercuric acetate to allow estimation of endogenous enzyme activity. The MMP-9 assays were validated for sputum. Samples spiked with exogenous MMP-9 (Lot#40011-70; Wyeth, USA) showed bias of <11% with 101-110% recovery; inter-assay CV was <8.8% and intra-assay CV was <7.9%; concentrations were stable up to 5 freeze-thaw cycles. Sputum cell MMP-9 expression levels (Affymetrix number 203936_s_at, on U133 + 2 chips) were measured in RNA isolated from airway inflammatory infiltrate cells harvested from induced sputum in healthy never smokers (n = 15), healthy smokers (n = 13), smokers with moderate to severe COPD (n = 15) and ex-smokers with moderate to severe COPD (n = 12). Expression levels were compared after global normalisation.


Variables were summarised as median (inter-quartile range). Values were compared between patient subgroups using two-sample Wilcoxon tests or Kruskal-Wallis test. Associations of MMP-9 with biomarkers were assessed using Spearman rank correlation coefficient with bootstrap 95% confidence intervals. All analyses were carried out in R version 2.11.0 [16].


Baseline demographics

Demographics and baseline characteristics are previously reported [7]. Briefly, median (IQR) age [years] of COPD volunteers was 65 (61.2, 68.9), healthy never smokers 49.9 (42.1, 55.8) and healthy smokers 53.3 (45.1, 57.8). In healthy never smokers FEV1% predicted median (IQR) was 105.5 (95.2, 115.0) and in healthy smokers this was 92.5 (87.5, 100.2). Lung function in the COPD group was as follows: median (IQR) post-bronchodilator FEV1% predicted, 65.0 (48.0-80.0); post-bronchodilator FEV1/FVC ratio, 64.0 (50.0-67.0); DLCO% predicted, 60.0 (47.5-70.0).

Sputum MMP-9 concentrations and activity

Sputum MMP-9 concentrations were increased in COPD subjects compared to healthy never smokers (p = 0.007), but were similar to healthy smokers (p = 0.343) (Table 1). Sputum MMP-9 enzyme activity was increased in ex-smokers with COPD compared to healthy never smokers (p < 0.001). Ex-smokers with COPD had higher concentrations and activity of sputum MMP-9 than current smokers with COPD (p = 0.002 and p < 0.001 respectively). Sputum MMP-9 concentrations and activity did not differ significantly between mild, moderate and severe COPD groups (data not shown). The MMP-9 protein concentration and activity did not correlate significantly with FEV1 or DLco% predicted. The extent of emphysema (% LAA −950) was significantly associated with sputum MMP-9 protein concentration [r = 0.442 (0.171, 0.634), p = 0.020,)] (Figure 1) and MMP-9 activity [r = 0.447 (0.219, 0.643), p = 0.010]. Sputum MMP-9 protein concentration, r = 0.724 (0.557, 0.839), p < 0.001,)] and MMP-9 activity, r = 0.682 (0.520, 0.800), p < 0.001, were associated with the percentage of sputum neutrophils. The sputum MMP-9 protein concentration correlated with sputum cell MMP-9 mRNA expression [r = 0.510 (0.292, 0.664), p < 0.001].
Table 1

Sputum MMP-9 concentrations and activity in sputum fluid from patients with COPD and healthy controls [Median (IQR)]


MMP-9 (ng/mL)

MMP-9 activity (ng/mL)

Healthy Control


49.80 (26.35, 136.50)

18.90 (12.50, 38.35)

Never smoker

34.05 (24.45, 131.00)

16.60 (12.50, 28.42)


69.00 (38.65, 184.00)

18.90 (13.40, 46.45)

p value 1

p = 0.161

p = 0.285



137.50 (45.52, 362.95)

26.65 (12.50, 51.85)

Ex- smoker

214.75 (101.12, 445.05)

42.10 (26.02, 116.10)


56.10 (28.90, 190.70)

12.50 (12.50, 32.52)

p value 2

p = 0.002

p < 0.001

p value 3

p = 0.007

p = 0.187

p value 4

p = 0.343

p = 0.787

p value 5

p < 0.001

p < 0.001

p value 6

p = 0.617

p = 0.086

1 Healthy smokers vs. healthy never smoker; 2 COPD smokers vs COPD ex-smokers;

3 All COPD subjects vs. healthy never smokers; 4 All COPD subjects vs. healthy smokers;

5 COPD ex-smokers vs. healthy never smokers; 6 COPD smokers vs. healthy smokers.
Figure 1

Correlation of sputum MMP-9 concentration (ng/ml) with computed tomography measure of emphysema [the low attenuation areas below −950 Hounsfield Units taken as an index of emphysema (% LAA −950) [r = 0.442 (0.171, 0.634), p = 0.020)].

Sputum MMP-9 mRNA expression

Sputum cell MMP-9 expression levels [median (IQR)] normalized fluorescent intensity units]) were significantly greater in ex-smokers with COPD, [4622 (3161, 5962)], current smokers with COPD, [5085 (4378, 9338)] and healthy smokers, [4111 (1623, 6202)] compared with healthy never smokers, [1650 (1023, 3443)]; (p = 0.001 for each). Sputum MMP-9 expression levels correlated negatively with post-bronchodilator FEV1% predicted [r = −0.530, (95% CI −0.686, -0.327), p < 0.001], post-bronchodilator FEV1/FVC [(r = −0.551 (−0.701, -0.354], p < 0.001], and DLco [r = −0.399 (−0.539, -0.102), p = 0.048], (Figure 2) but were not significantly associated with the CT extent of emphysema [r = 0.266 (−0.020, 0.446), p = 0.115].
Figure 2

Correlation of sputum MMP-9 mRNA expression and diffusing capacity for carbon monoxide (DLco) % predicted [r = −0.399 (−0.539, -0.102), p = 0.048].


This study found that sputum MMP-9 concentrations and mRNA expression in COPD are significantly greater than in healthy never-smokers, that sputum MMP-9 concentrations are directly associated with the extent of emphysema measured by CT and that higher MMP-9 expression levels are associated with greater airflow obstruction and reduced diffusing capacity. Taken together, these findings provide indirect evidence for a link between MMP-9 and disease severity in COPD.

Previous studies have reported increased MMP-9 protein concentrations and/or activity in current smokers with COPD compared to healthy smokers [8, 9]. In contrast to the finding from these studies we found that sputum MMP-9 concentrations and activity in COPD subjects were similar to healthy smokers. There are differences in the severity of disease and smoking status between these studies. The patients with COPD studied previously [8, 9] had in general more severe disease compared to the participants in our study, which could explain the different results [17]. Both current and ex-smokers with COPD were recruited to the present study, whereas previous studies included only current smokers with COPD [8, 9]. Smoking status is however unlikely to explain the different results as ex-smokers had higher MMP-9 levels and activity than current smokers with COPD. The ex-smokers with COPD in the present study had more severe disease, as assessed by the extent of emphysema on CT, which may explain the higher sputum MMP-9 concentrations in this group.

The severity of COPD, when assessed by the extent of emphysema on CT scanning, but not by spirometry values, was significantly associated with sputum MMP-9 concentrations and activity. We found no significant association between sputum MMP-9 levels and DLco; although the extent of emphysema measured by CT often correlates with DLco in COPD, this association is not always found. The findings of an association of greater MMP-9 expression in moderate to severe disease with greater airflow obstruction and reduced diffusing capacity as well as more extensive emphysema on CT scanning with MMP-9 concentrations suggests a role for MMP-9 in the pathogenesis of emphysema. Alternatively, increased sputum MMP-9 may be a marker of disease severity in patients who already have emphysema. Long-term clinical trials of MMP-9 inhibitors in COPD would help establish whether blocking MMP-9 activity attenuates the development and progression of emphysema. Previously, we reported that sputum MMP-12 concentrations and activity in patients with COPD are directly associated with the extent of emphysema measured by CT [7] suggesting that blocking both MMP-9 and MMP-12 may be more effective than inhibiting either MMP-9 or MMP-12 alone.

In conclusion, disease severity in COPD when assessed by the extent of emphysema measured by CT is directly associated with sputum MMP-9 concentrations. Interventions directed at inhibiting MMP-9 activity, either alone or in combination with MMP-12 blockers, should be investigated for their potential to attenuate the development or progression of emphysema.



This work was funded by an award (INF-GU-090) from the Translational Medicine Research Collaboration – a consortium made up of the Universities of Glasgow, Edinburgh, Aberdeen and Dundee and the four associated NHS Health Boards (Greater Glasgow & Clyde, Lothian, Grampian and Tayside), Scottish Enterprise and Pfizer (formerly Wyeth) and supported financially by NHS Research Scotland (NRS), through the Scottish Primary Care Research Network. The authors would like to thank Joyce Thompson, Jane Lafferty, Maureen Brannigan and Kathleen Masterson for sample collection and Lisa Jolly and Iona Donnelly for processing the samples.

Authors’ Affiliations

Immunology, Institute of Infection, Immunity & Inflammation, University of Glasgow and Gartnavel General Hospital
Pfizer Research/Translational Medicine Research Collaboration
Pfizer Research/Translational Medicine Research Collaboration
Pfizer Research/Translational Medicine Research Collaboration
Robertson Centre for Biostatistics, University of Glasgow
MRC Centre for Inflammation Research, Medical Physics and Clinical Radiology, University of Edinburgh
Radiology Department, Gartnavel General Hospital
Ear Nose and Throat Department, Gartnavel General Hospital


  1. Boschetto P, Quintavalle S, Zeni E, Leprotti S, Potena A, Ballerin L, Papi A, Palladini G, Luisetti M, Annovazzi L: Association between markers of emphysema and more severe chronic obstructive pulmonary disease. Thorax 2006, 61: 1037–1042. 10.1136/thx.2006.058321PubMed CentralPubMedView ArticleGoogle Scholar
  2. Elias JA, Kang MJ, Crouthers K, Homer R, Lee CG: State of the art. Mechanistic heterogeneity in chronic obstructive pulmonary disease: Insights from transgenic mice. Proc Am Thorac Soc 2006, 3: 494–498. 10.1513/pats.200603-068MSPubMedView ArticleGoogle Scholar
  3. Demedts IK, Brusselle GG, Bracke KR, Vermaelen KY, Pauwels RA: Matrix metalloproteinases in asthma and COPD. Curr Opin Pharmacol 2005, 5: 257–263. 10.1016/j.coph.2004.12.005PubMedView ArticleGoogle Scholar
  4. Elkington PTG, Friedland JS: Matrix metalloproteinases in destructive pulmonary pathology. Thorax 2006, 61: 259–266. 10.1136/thx.2005.051979PubMed CentralPubMedView ArticleGoogle Scholar
  5. Gueders MM, Foidart J-M, Noel A, Cataldo DD: Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPss in the respiratory tract: Potential implications in asthma and other lung diseases. Eur J Pharmacol 2006, 533: 133–144. 10.1016/j.ejphar.2005.12.082PubMedView ArticleGoogle Scholar
  6. Lavigne MC, Thakker P, Gunn J, Wong A, Miyashiro JS, Wasserman AM, Wei S-Q, Pelker JW, Kobayashi M, Eppihimer MJ: Human bronchial epithelial cells express and secrete MMP-12. Bioch Biophy Res Commun 2004, 324: 534–546. 10.1016/j.bbrc.2004.09.080View ArticleGoogle Scholar
  7. Chaudhuri R, McSharry C, Brady J, Donnelly I, Grierson C, McGuinness S, Jolly L, Weir CJ, Messow CM, Spears M: Sputum matrix metalloproteinase-12 in patients with chronic obstructive pulmonary disease and asthma: Relationship to disease severity. J Allergy Clin Immunol 2012, 129: 655–663. 10.1016/j.jaci.2011.12.996PubMedView ArticleGoogle Scholar
  8. Lowrey GE, Henderson N, Blakey JD, Corne JM, Johnson SR: MMP-9 protein level does not reflect overall MMP activity in the airways of patients with COPD. Resp Med 2008, 102: 845–851. 10.1016/j.rmed.2008.01.006View ArticleGoogle Scholar
  9. Culpitt SV, Rogers DF, Traves SL, Barnes PJ, Donnelly LE: Sputum matrix metalloproteases: Comparison between chronic obstructive pulmonary disease and asthma. Resp Med 2005, 99: 703–710. 10.1016/j.rmed.2004.10.022View ArticleGoogle Scholar
  10. Atkinson JJ, Lutey BA, Suzuki Y, Toennies HM, Kelley DG, Kobayashi DK, Ijem WG, Deslee G, Moore CH, Jacobs ME: The role of matrix metalloproteinase-9 in cigarette smoke-induced emphysema. Am J Respir Crit Care Med 2011, 183: 876–884. 10.1164/rccm.201005-0718OCPubMed CentralPubMedView ArticleGoogle Scholar
  11. Global strategy for diagnosis, management, and prevention of COPD. 2010.
  12. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P: ATS/ERS task force standardisation of lung function testing: Standardisation of spirometry. Eur Respir J 2005, 26: 319–338. 10.1183/09031936.05.00034805PubMedView ArticleGoogle Scholar
  13. Mair G, Miller JJ, McAllister D, Maclay J, Connell M, Murchison JT, MacNee W: Computed tomographic emphysema distribution: Relationship to clinical features in a cohort of smokers. Eur Respir J 2009, 33: 536–542. 10.1183/09031936.00111808PubMedView ArticleGoogle Scholar
  14. Matsuoka S, Yamashiro T, Washko GR, Kurihara Y, Nakajima Y, Hatabu H: Quantitative ct assessment of chronic obstructive pulmonary disease1. Radiographics 2010, 30: 55–66. 10.1148/rg.301095110PubMedView ArticleGoogle Scholar
  15. Coxson HO, Mayo J, Lam S, Santyr G, Parraga G, Sin DD: New and current clinical imaging techniques to study chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180: 588–597. 10.1164/rccm.200901-0159PPPubMedView ArticleGoogle Scholar
  16. R: A language and environment for statistical computing. 2012.
  17. Ilumets H, Rytilä P, Demedts I, Brusselle G, Sovijärvi A, Myllärniemi M, Sorsa T, Kinnula V: Matrix metalloproteinases −8, -9 and −12 in smokers and patients with stage 0 COPD. Int J Chron Obstruct Pulmon Dis 2007, 2: 369–379.PubMed CentralPubMedGoogle Scholar


© Chaudhuri et al.; licensee Springer. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.